Once weekly DPP 4 inhibitor for Diabetes Treatment
One of the challenges in treating a chronic disease such as diabetes is pill adherence. It should be effective, well-tolerated oral antihyperglycemic agent. It should be effective in lowering HbA1c levels with a favorable safety profile. It has the potential to improve patient adherence, which might translate into better glycemic control and disease outcomes. So, a once-weekly drug may be a convenient. After 24 weeks of treatment, patients who received had a significantly greater mean reduction in HbA1c from baseline. The major treatment effect was observed by week 12. It should not associated with symptomatic or severe hypoglycemia or any appreciative change in weight. Merck is now conducting 10 phase 3 clinical trials in approximately 8000 patients with type 2 diabetes, according to a company statement.
Youtube Channel: https://www.youtube.com/user/drzulfiquar